Prostate Cancer Trials


TheraP aims to compare the activity and safety of Lutetium-177 PSMA617 (Lu-PSMA) versus cabazitaxel therapy in metastatic castration resistant prostate cancer.

The ENZAMET trial is for men with metastatic prostate cancer commencing androgen deprivation therapy.

The ENZARAD trial is for men with localised prostate cancer at high risk for recurrence deemed suitable for external beam radiation therapy.

This trial is for men with localised prostate cancer at high risk for recurrence deemed suitable for external beam radiation therapy.

© ANZUP 2018. All rights reserved.